Table 2.

Clinical characteristics of patients with MA-ILD who responded to or failed conventional treatment (n = 54). Values are n unless otherwise specified.

Clinical CharacteristicsResponders, n = 31Nonresponders, n = 23p
Age at onset of myositis, yrs46.842.20.34
Smoking history
Baseline CK, U/l2588.93431.00.20
Baseline aldolase29.634.40.29
Serologic data
PFT, %
CT chest
  Honeycombing absent21170.62
  Honeycombing present106
Lung histopathology
Conventional DMARD
  • * COP with NSIP, COP with hypersensitivity pneumonitis, and COP with diffuse alveolar damage. MA-ILD: myositis-associated interstitial lung disease; CADM: clinically amyopathic dermatomyositis; CK: creatine kinase; ANA: antinuclear antibody; SRP: signal recognition particle; PFT: pulmonary function test; FVC: forced vital capacity; TLC: total lung capacity; CT: computed tomography; COP: cryptogenic organizing pneumonia; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; DMARD: disease-modifying antirheumatic drugs; AZA: azathioprine; MTX: methotrexate; MMF: mycophenolate mofetil.